Wilms' tumor 1 enhances Cisplatin-resistance of advanced NSCLC

Chen Wu,Yonggong Wang,Yang Xia,Shaohua He,Zhiqiang Wang,Yijiang Chen,Changping Wu,Yongqian Shu,Jingting Jiang
DOI: https://doi.org/10.1016/j.febslet.2014.10.026
2014-12-20
Abstract:Wilms' tumor 1 (WT1) is an oncogene that has been correlated with tumor progression, bad prognosis and chemo-resistance in Non-Small-Cell lung cancer (NSCLC). Here, we found that WT1 expression is significantly higher in NSCLCs than in benign controls, and that Cisplatin-resistant patients display a notable increase in WT1 expression following relapse. In vitro, WT1 levels were associated with the IC50 of NSCLC cells and increased along with treatment time and dose of Cisplatin. Furthermore, WT1 enhanced Major Vault Protein (MVP) transcription via binding to its promoter. Therefore, WT1 may be a potential therapeutic target for solving resistance.
What problem does this paper attempt to address?